Evidence map›Paper›PMID 39091061›Full record

ArticleProteomics2024

Deep phosphotyrosine characterisation of primary murine T cells using broad spectrum optimisation of selective triggering.

Aurora Callahan, Xien Yu Chua, Alijah A Griffith, Tobias Hildebrandt, Guoping Fu, Mengzhou Hu, Renren Wen, Arthur R Salomon

Abstract read
In one paragraph

Article in Proteomics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Aurora CallahanDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, Rhode Island, USA.
Xien Yu ChuaDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, Rhode Island, USA.
Alijah A GriffithDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, Rhode Island, USA.
Tobias HildebrandtDepartment of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, Rhode Island, USA.
Guoping FuVersiti Blood Research Institute, Milwaukee, Wisconsin, USA.
Mengzhou HuDepartment of Molecular Pharmacology, Physiology, and Biotechnology, Brown University, Providence, Rhode Island, USA.
Renren WenVersiti Blood Research Institute, Milwaukee, Wisconsin, USA.
Arthur R SalomonDepartment of Molecular Biology, Cell Biology and Biochemistry, Brown University, Providence, Rhode Island, USA.ORCID 0000-0002-7223-8996

Funding

Understand the metabolic fitness of naïve T cellsP01AI091580 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JEROEN ROOSE · 2011 to 2026
$31.1M
Translational Regulation in Normal Erythropoiesis and Diamond Blackfan AnemiaP20GM121293 · NIGMS · ARKANSAS CHILDREN'S HOSPITAL RES INST · PI Alan Tackett · 2017 to 2026
$27.6M
Supplement for Google cloud build-outR24GM137786 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI Alan Tackett · 2020 to 2026
$15.4M
Phosphoproteomic Analysis of T Cell Activation PathwaysR01AI083636 · NIAID · BROWN UNIVERSITY · PI SALOMON, ARTHUR ROBERT · 2010 to 2021
$4.0M
Molecular Basis of the Humoral Immune Response in Heparin-Induced ThrombocytopeniaR01HL148120 · NHLBI · VERSITI WISCONSIN, INC. · PI Renren Wen · 2019 to 2026
$3.8M
Predoctoral Training in Molecular, Cellular, and Biochemical SciencesT32GM136566 · NIGMS · BROWN UNIVERSITY · PI Mark Aikens Johnson, Erica Nicole Larschan · 2020 to 2026
$3.1M
B-cell response and thrombotic complications in COVID-19R01HL161127 · NHLBI · VERSITI WISCONSIN, INC. · PI WEN, RENREN · 2022 to 2025
$2.6M
NHLBI NIH HHS R01 HL148120NHLBI NIH HHS R01 HL161127NIAID NIH HHS P01 AI091580NIAID NIH HHS R01 AI083636NIGMS NIH HHS P20 GM121293NIGMS NIH HHS R24 GM137786NIGMS NIH HHS T32 GM136566NIH HHS HL148120NIH HHS HL161127NIH HHS P01AI091580NIH HHS P20GM121293NIH HHS R01AI083636NIH HHS R24GM137786NIH HHS T32GM136566Sidney E. Frank Fellowship
6 · The paper itself

Abstract

Sequencing the tyrosine phosphoproteome using MS-based proteomics is challenging due to the low abundance of tyrosine phosphorylation in cells, a challenge compounded in scarce samples like primary cells or clinical samples. The broad-spectrum optimisation of selective triggering (BOOST) method was recently developed to increase phosphotyrosine sequencing in low protein input samples by leveraging tandem mass tags (TMT), phosphotyrosine enrichment, and a phosphotyrosine-loaded carrier channel. Here, we demonstrate the viability of BOOST in T cell receptor (TCR)-stimulated primary murine T cells by benchmarking the accuracy and precision of the BOOST method and discerning significant alterations in the phosphoproteome associated with receptor stimulation. Using 1 mg of protein input (about 20 million cells) and BOOST, we identify and precisely quantify more than 2000 unique pY sites compared to about 300 unique pY sites in non-BOOST control samples. We show that although replicate variation increases when using the BOOST method, BOOST does not jeopardise quantitative precision or the ability to determine statistical significance for peptides measured in triplicate. Many pY previously uncharacterised sites on important T cell signalling proteins are quantified using BOOST, and we identify new TCR responsive pY sites observable only with BOOST. Finally, we determine that the phase-spectrum deconvolution method on Orbitrap instruments can impair pY quantitation in BOOST experiments.

Indexed as

PhosphotyrosineProteomicsReceptors, Antigen, T-CellT-LymphocytesAnimalsMiceMice, Inbred C57BLPhosphoproteinsPhosphorylationProteomeTandem Mass SpectrometryPhosphoproteinsPhosphotyrosineProteomeReceptors, Antigen, T-CellBOOSTphase‐constrained spectrum deconvolutionphosphotyrosine proteomicsprimary T celltandem mass tags

Identifiers

PMID39091061
PMCPMC11684461

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.